Our analysis of BRAF mutant melanoma cells did not reveal any significant effect of CDK4/6 inhibition on glycolysis, nor did it alter the glycolytic response to BRAF/MEK inhibition, as indicated by no change in lactate production, extracellular acidification rate or expression of glycolysis pathway components. This evidence concerns the gene MAP2K7 and melanoma.